Identification of a Novel CD8+ T Cell Epitope Derived from Cancer‐Testis Antigen MAGE‐4 in Oesophageal Carcinoma

Wu, Zongyin; Gao, Yanfeng; Wu, Yahong; Liu, W.; Sun, Menghong; Zhai, Mingxia; Qi, Yuanming; Ye, Y.

doi:10.1111/j.1365-3083.2011.02606.x

Cited by 9 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies showed that administering autologous CD4 (+) T cells could express an MHC class II restricted antitumor TCR that targets MAGE-A3. [30] Wu et al [31] found that the peptide p286–1Y2L9L of CD8+ T cell epitope was derived from cancer-testis antigen MAGE-4. [31] The above results indicated that MAGE-A3/4/9/11 played an important role in regulating the immune response and process.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics

et al. 2019

View full text Add to dashboard Cite

Background: Melanoma-associated antigen-A (MAGE-A) was recognized as high-expressed in many solid tumors including esophageal carcinoma (EC), nevertheless, was reported to be low/not-expressed in normal tissues. Thus, it was considered as an extraordinary appropriate target for treatment especially in immunotherapy. Therefore, it demanded more detail knowledge on the precise function of MAGE-A. Methods: In this study, we used the data from the Cancer Genome Atlas dataset (TCGA-ESCA) to analyze the expression and survival for MAGE A3/4/11 (the subtype of MAGE-A) using the online tool of UALCAN. Furthermore, the high-throughput sequencing data of the patients with esophageal squamous-cell carcinoma (ESCC) from TCGA dataset were performed to analyze the correlation test, gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of MAGE A3/4/9/11 using LinkeDomics (online tool) and ClueGO (inner software of Cytoscape). Finally, relative gene expressions of MAGE A3/4/9/11 were verified by quantitative real-time PCR (q-PCR) in the patients with EC. Results: MAGE A3/4/11 was high-expressed in tissues of patients with ESCC, and there was no difference in survival time for patients between the high-expressed with the low/medium-expressed. The Go enrichment analysis showed that the 4 MAGE-A subtypes (MAGE-A3/4/9/11) were enriched in the regulation of the adaptive immune response, translational initiation, interleukin-4 production, response to type I interferon, and skin development, respectively. The KEGG results showed that they were enriched in T cell receptor signaling pathway (MAGE-A3), Th1 and Th2 differentiation, antigen processing and presentation (MAGE-A4), cytokine-cytokine receptor interaction (MAGE-A9), and chemokine signaling pathway (MAGE-A11). Conclusion: MAGE A3/4/9/11 was high-expressed in EC, and were enrolled in the regulation of immune response. They may consider as candidate immune target for EC treatment and provided the messages for further research in the function of MAGE-A.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[30] Wu et al [31] found that the peptide p286–1Y2L9L of CD8+ T cell epitope was derived from cancer-testis antigen MAGE-4. [31] The above results indicated that MAGE-A3/4/9/11 played an important role in regulating the immune response and process. The 4 antigens showed theoretically proper immune target for EC immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Cytotoxic activity of induced T cells was tested based on the quantitation of LDH release using the nonradioactive cytotoxicity assay kit (Promega, USA) at the gradient E/T ratio [29, 31]. Target cells which expressed different levels of MTA1 or peptide-pulsed T2 cells were used as target cells.…”

Section: Methodsmentioning

confidence: 99%

HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response

Zhai

Zhou

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

Overexpression of metastasis-associated protein 1 (MTA1) has been observed in many human malignancies and is significantly related to tumor invasion and metastasis, therapeutic resistance to radiation and chemotherapy, making MTA1 an ideal candidate tumor antigen. We identified several human leukocyte antigen- (HLA-) A2-restricted epitopes in MTA1 and evaluated their binding ability to HLA-A∗0201 molecules. Subsequently, a recombinant fragment encompassing the dominant epitopes, MTA1(1–283), was expressed, and the abilities of the selected epitopes of MTA1 and the MTA1(1–283) fragment to induce cytotoxic T lymphocytes (CTLs) were examined. Our results indicated that the epitopes and MTA1(1–283) fragment elicited HLA-A2-restricted and antigen-specific CTL responses both in vitro and in vivo. The new epitopes identified here may help promote the development of new therapeutic vaccines for HLA-A2+ patients expressing MTA1.

show abstract

“…Testing HLA-A2binding avidity of epitopes HLA-A2 binding of epitopes was performed as previously described by Wu et al (22) with minor adjustments. In short, 0.15 × 10 6 T2 cells were incubated in serum-free medium supplemented with b 2 -microglobulin (3 mg/ml; Sigma-Aldrich, Amsterdam, the Netherlands) and exposed to titrated amounts of epitope ranging from 30 nM to 30 mM for 3 h at 37 • C, after which T2 cells were stained with antiHLA-A2 (1:20, BB7.2, BD Pharmingen) on ice in the dark.…”

Section: Testing Epitope-specific Responses Of T Cellsmentioning

confidence: 99%

Detection of Low-Frequency Epitope-Specific T Cells in Blood of Healthy Individuals according to an Optimized In Vitro Amplification System

Mahajan

Kortleve

Debets

et al. 2022

The Journal of Immunology

View full text Add to dashboard Cite

Detection and amplification of epitope-specific T cells hold great promise for diagnosis and therapy of cancer patients. Currently, measurement and retrieval of epitope-specific T cells is hampered by limited availability of patients’ biomaterials and lack of sensitive and easy-to-implement T cell priming and expansion. We have developed an in vitro T cell amplification system starting from healthy donor blood and tested different subsets and ratios of autologous T cells and APCs as well as the resting period between amplification cycles. We demonstrated in 10 different donors significantly enhanced frequency of T cells specific for MelanA/HLA-A2, which relied on coculturing of naive T cells and CD11c+ dendritic cells in a 1:1 ratio followed by three weekly amplification cycles using the effluent of the naive T cell sort as APCs, a 24-h rest period prior to every reamplification cycle, and IFN-γ production as a readout for epitope-specific T cells. Using this system, MelanA/HLA-A2–specific T cells were enriched by 200-fold, measuring up to 20–60% of all T cells. We extended this system to enrich NY-ESO-1/HLA-A2– and BMLF-1/HLA-A2–specific T cells, examples of a cancer germline Ag and an oncoviral Ag differing in their ability to bind to HLA-A2 and the presence of specific T cells in the naive and, in case of BMLF-1, also the Ag-experienced repertoire. Collectively, we have developed a sensitive and easy-to-implement in vitro T cell amplification method to enrich epitope-specific T cells that is expected to facilitate research and clinical utility regarding T cell diagnosis and treatments.

show abstract

Identification of a Novel CD8+ T Cell Epitope Derived from Cancer‐Testis Antigen MAGE‐4 in Oesophageal Carcinoma

Cited by 9 publications

References 39 publications

Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics

Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics

HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response

Detection of Low-Frequency Epitope-Specific T Cells in Blood of Healthy Individuals according to an Optimized In Vitro Amplification System

Contact Info

Product

Resources

About